Shares of Dr Reddy’s Laboratories will remain in focus following receipt of establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico. The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient plant in Mexico by the United States Food and Drug Administration was completed with zero observations. Shareholders of DRL will closely monitor the development.
What to Watch. Eyes on DRL after Mexico unit gets notice
Published on
April 10, 2018 16:05
Tags